Pre-diagnostic serum levels of inflammation markers and risk of ovarian cancer in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial.

@article{Trabert2014PrediagnosticSL,
  title={Pre-diagnostic serum levels of inflammation markers and risk of ovarian cancer in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial.},
  author={B Trabert and Ligia A. Pinto and Patricia A Hartge and Troy J. Kemp and Amanda Black and Mark E. Sherman and Louise A Brinton and Ruth M. Pfeiffer and Meredith S. Shiels and Anil K Chaturvedi and Allan Hildesheim and Nicolas Wentzensen},
  journal={Gynecologic oncology},
  year={2014},
  volume={135 2},
  pages={297-304}
}
OBJECTIVE Pro-inflammatory mechanisms may explain the increased ovarian cancer risk linked to more lifetime ovulations, endometriosis, and exposure to talc and asbestos, as well as decreased risk with non-steroidal anti-inflammatory drugs. Limited data are available to estimate ovarian cancer risk associated with levels of circulating inflammatory markers. METHODS We conducted a nested case-control study within the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Pre-diagnostic… CONTINUE READING